Microhealth

Microhealth is dedicated to developing innovative digital therapeutics specifically designed to address critical unmet medical needs within the fields of hematology and oncology. Our approach involves several key stages. Initially, we establish comprehensive networks comprising both doctors and patients, enabling us to effectively track, predict, and ultimately prevent disease progression. Subsequently, we rigorously validate the safety and efficacy of our therapeutic interventions through pivotal clinical studies, ensuring adherence to regulatory standards and paving the way for regulatory clearance as Software as a Medical Device (SaMD). Our ultimate goal is to commercialize these validated products as prescription digital therapeutics (DTx), making them accessible to patients in need. Currently, Microhealth stands as a leader in digital hematology, boasting a hemophilia network that encompasses 33% of all relevant patients and healthcare providers across the United States. We have successfully outperformed over 20 competitors, including numerous Fortune 500 companies, and have established partnerships with industry giants such as Sanofi, Bayer, Novo Nordisk, Biogen, and Roche.